Last updated 2026-08-21
- Raised $2M Pre-Seed round, Dec 2023
Total raised
$2.0M
Stage
—
Founded
2022
Headcount
—
HQ
Boston, United States
Sector
Biotechnology
About
Envoya is a biotechnology company at the forefront of drug delivery innovation, developing a next-generation nanoparticle platform that enhances the delivery of nucleic acids and other therapeutic agents. The company aims to revolutionize gene therapy through its cutting-edge combination of biopolymer-nanoparticles and artificial intelligence, offering a safer and more efficient alternative to current delivery technologies. Envoya's platform has shown promising results in early preclinical experiments in multiple oncology indications and is designed to overcome limitations like safety concerns, limited payload capacities, and restricted tissue-targeting.
Funding history · 1 round · $2.0M total
2023-12
Pre-Seed
$2.0M
Q&A
- What is Envoya Inc.'s primary focus?
- Envoya Inc. is a biotechnology company focused on developing an AI-enabled gene therapy drug delivery platform using next-generation nanoparticle technology.
- When was Envoya Inc. founded?
- Envoya Inc. was founded in 2022.
- Where is Envoya Inc. headquartered?
- Envoya Inc. is headquartered in Boston, United States.
- How much funding has Envoya Inc. raised to date?
- Envoya Inc. has raised a total of $2,000,000 USD.
- When did Envoya Inc. complete its Pre-Seed funding round?
- Envoya Inc. completed a Pre-Seed funding round in December 2023, raising $2,000,000.
- Who are the founders of Envoya Inc.?
- The founders of Envoya Inc. are Shira Orr, who serves as Founder and CEO, and Eran Orr, who is Co-founder and Chairman of the Board.
- What markets does Envoya Inc.'s technology target?
- Envoya Inc.'s technology targets markets such as Oncology and Rare Genetic Diseases.
- What is the core technology of Envoya Inc.?
- Envoya Inc.'s core technology is an AI-driven drug delivery platform utilizing biopolymer-nanoparticles.
Team · 6
Shira Orr
Founder · Founder and CEO
Eran Orr
Founder · Co-founder and Chairman of the Board
Ori Shaashua
Chief Product Officer (CPO)
Alysa Langburt
VP of Strategic Partnerships
Trinayan Kashyap
VP of Research
Gilad Meiri
Board Member and Investor
Sectors & technology
Primary sector
Biotechnology
Technologies
Target customers
Business model
B2B
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | envoyabio.com |
|---|
Identifiers & details
| Founded | 2022 |
|---|